Clovis Oncology, Inc., launched on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. (NASDAQ:CLVS) in a research report sent to investors on Thursday. They now have a $93.00 price objective on the biopharmaceutical company's stock. The stock of Costco Wholesale Corporation (NASDAQ:COST) has "Hold" rating given on Wednesday, June 28 by Deutsche Bank.
Clovis Oncology (NASDAQ:CLVS) previously announced its periodic earnings reports on early Wed, Aug 2nd. Cann started coverage on shares of Clovis Oncology in a research report on Thursday, June 22nd. They issued a "market perform" rating on the stock. Janney Montgomery Scott raised shares of Clovis Oncology from a "neutral" rating to a "buy" rating in a research note on Tuesday, June 20th. Zacks Investment Research lowered shares of Clovis Oncology from a "buy" rating to a "hold" rating in a research report on Thursday, July 13th. They set a buy rating and a $125.00 price target for the company. Eight investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Clovis Oncology now has an average rating of "Buy" and a consensus target price of $81.59. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company's stock worth $253,000 after buying an additional 2,000 shares during the last quarter. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has "Neutral" rating given on Monday, November 16 by Mizuho. Company's valuation is $3.49 B. Company's 50 Day SMA price is $87.91 and the 200 day SMA is $66.98. Equity analyst Chardan Capital upgraded the stock and raised the price target on June 19 boosting the price target from $15.00 to $85.00 and moving the rating from "Sell" to "Outperform". Bancorporation Of America De reported 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). After $-1.33 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -3.01% EPS growth. The firm had revenue of $14.62 million during the quarter, compared to analysts' expectations of $13.07 million. Clovis Oncology's quarterly revenue was down 32.5% compared to the same quarter a year ago. The Partner Investment Management Lp holds 25,609 shares with $1.14M value, up from 17,979 last quarter. Equities research analysts expect that Clovis Oncology will post ($7.51) earnings per share for the current fiscal year. If you are viewing this story on another site, it was copied illegally and reposted in violation of worldwide copyright and trademark laws. "(NASDAQ:CLVS)" was reported by Stock Observer and is the sole property of of Stock Observer. Gillian C. Ivers-read, See Remarks sold $274,680 worth of shares at an average price of $91.56 on Monday the 17th. As of the end of the quarter Teachers Advisors, LLC had sold a total of 21,522 shares trimming its position 4.4%. Following the completion of the transaction, the insider now directly owns 203,583 shares in the company, valued at $9,647,798.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
In other Clovis Oncology news, Director James C. Blair sold 18,450 shares of the business's stock in a transaction on Friday, August 4th. The stock was sold at an average price of $78.61, for a total value of $1,450,354.50. Next Financial Group Inc acquired 2,397 shares as Costco Whsl Corp New (COST)'s stock rose 1.54%. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,450 shares of company stock valued at $2,052,665.
Stocks of Clovis Oncology, (NASDAQ:CLVS) have been issued a consensus rating of "Buy" by the twenty analysts that are presently covering the share, Marketbeat recommendation reports. Finally, Shell Asset Management Co. bought a new stake in shares of Clovis Oncology during the first quarter valued at $489,000. Putnam Invests Ltd Liability Company invested in 0% or 43,185 shares. Emerald Advisers Inc. PA purchased a new position in Clovis Oncology during the first quarter worth $14,489,000. The institutional investor owned 101,855 shares of the biopharmaceutical company's stock after selling 305,561 shares during the period. Clovis Oncology earned a daily sentiment score of 0.13 on Accern's scale. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company's stock valued at $177,000 after buying an additional 1,168 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Clovis Oncology during the fourth quarter valued at about $3,647,000. Company insiders own 17.40% of the company's stock. Alliancebernstein Ltd Partnership owns 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 46,040 shares.
Next Financial Group Inc decreased Select Sector Spdr Tr (XLE) stake by 6,336 shares to 12,771 valued at $962,000 in 2016Q4.
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets.